ArticleEuropean journal of nuclear medicine and molecular imaging2026
Survival effect of PET/CT-defined occult lymph node metastasis in the newly proposed ninth edition N descriptors: a multicentre study.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposeTo elucidate the potential reasons for the favourable prognosis of positron emission tomography/computed tomography (PET/CT)-defined occult N2 metastasis and its survival effect in the context of the newly proposed ninth edition N descriptors.
methodsA total of 3565 patients who underwent preoperative PET/CT and surgical resection for non-small cell lung cancer were retrospectively included. Survival analysis was conducted using the Kaplan-Meier method and Cox proportional hazards model.
resultsThe incidence of single-station involvement was significantly higher (p < .001) in occult N2 metastasis (117/191, 61.3%) compared to evident N2 metastasis (83/198, 41.9%). The survival rates of patients with occult N2a (single-station N2 involvement) and occult N2b (multiple-station N2 involvement) were comparable to those of patients with clinically evident N2a and N2b, respectively (adjusted p >.20 for all). Conversely, single-station involvement was associated with a markedly superior prognosis than multiple-station involvement, whether for patients with occult N2 metastasis (5-year overall survival [OS]: 62.7% vs 50.1%, adjusted p = .04) or patients with clinically evident N2 metastasis (5-year OS: 50.3% vs 36.2%, adjusted p = .03). Cox regression analysis of the pathological N2 population further indicated that multiple-station involvement was a more robust prognostic factor than occult lymph node metastasis.
conclusionsThe favourable prognosis of PET/CT-defined occult N2 metastasis may be attributed to the discrepancy in prognosis and proportion between occult N2a and clinically evident N2b. This external validation provided substantial evidence supporting the reasonableness and robustness of the newly proposed ninth edition N descriptors.
Indexed as
Identifiers
40986090What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.